OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
Bernard Hanseeuw, Rebecca A. Betensky, Heidi I.L. Jacobs, et al.
JAMA Neurology (2019) Vol. 76, Iss. 8, pp. 915-915
Open Access | Times Cited: 657
Bernard Hanseeuw, Rebecca A. Betensky, Heidi I.L. Jacobs, et al.
JAMA Neurology (2019) Vol. 76, Iss. 8, pp. 915-915
Open Access | Times Cited: 657
Showing 1-25 of 657 citing articles:
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Justin M. Long, David M. Holtzman
Cell (2019) Vol. 179, Iss. 2, pp. 312-339
Open Access | Times Cited: 2339
Justin M. Long, David M. Holtzman
Cell (2019) Vol. 179, Iss. 2, pp. 312-339
Open Access | Times Cited: 2339
2020 Alzheimer's disease facts and figures
In this phase, individuals have measurable brain changes that indicate the earliest signs of Alzheimer's disease, but they have not yet developed symptoms such as memory loss. Examples of measurable brain changes …, et al.
Alzheimer s & Dementia (2020) Vol. 16, Iss. 3, pp. 391-460
Open Access | Times Cited: 2138
In this phase, individuals have measurable brain changes that indicate the earliest signs of Alzheimer's disease, but they have not yet developed symptoms such as memory loss. Examples of measurable brain changes …, et al.
Alzheimer s & Dementia (2020) Vol. 16, Iss. 3, pp. 391-460
Open Access | Times Cited: 2138
2023 Alzheimer's disease facts and figures
Alzheimer s & Dementia (2023) Vol. 19, Iss. 4, pp. 1598-1695
Open Access | Times Cited: 1986
Alzheimer s & Dementia (2023) Vol. 19, Iss. 4, pp. 1598-1695
Open Access | Times Cited: 1986
2022 Alzheimer's disease facts and figures
Alzheimer s & Dementia (2022) Vol. 18, Iss. 4, pp. 700-789
Closed Access | Times Cited: 1961
Alzheimer s & Dementia (2022) Vol. 18, Iss. 4, pp. 700-789
Closed Access | Times Cited: 1961
In the past, was often used to describe the dementia phase of the disease. Today we know that dementia is only …, Adult Disease, et al.
Alzheimer s & Dementia (2021) Vol. 17, Iss. 3, pp. 327-406
Closed Access | Times Cited: 1910
Alzheimer disease
David S. Knopman, Hélène Amieva, Ronald C. Petersen, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 1489
David S. Knopman, Hélène Amieva, Ronald C. Petersen, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 1489
The Amyloid-β Pathway in Alzheimer’s Disease
Harald Hampel, John Hardy, Kaj Blennow, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 10, pp. 5481-5503
Open Access | Times Cited: 1033
Harald Hampel, John Hardy, Kaj Blennow, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 10, pp. 5481-5503
Open Access | Times Cited: 1033
Synergy between amyloid-β and tau in Alzheimer’s disease
Marc Aurel Busche, Bradley T. Hyman
Nature Neuroscience (2020) Vol. 23, Iss. 10, pp. 1183-1193
Closed Access | Times Cited: 856
Marc Aurel Busche, Bradley T. Hyman
Nature Neuroscience (2020) Vol. 23, Iss. 10, pp. 1183-1193
Closed Access | Times Cited: 856
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Bruno Dubois, Nicolas Villain, Giovanni B. Frisoni, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 6, pp. 484-496
Open Access | Times Cited: 689
Bruno Dubois, Nicolas Villain, Giovanni B. Frisoni, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 6, pp. 484-496
Open Access | Times Cited: 689
The β-Secretase BACE1 in Alzheimer’s Disease
Harald Hampel, Robert Vassar, Bart De Strooper, et al.
Biological Psychiatry (2020) Vol. 89, Iss. 8, pp. 745-756
Open Access | Times Cited: 492
Harald Hampel, Robert Vassar, Bart De Strooper, et al.
Biological Psychiatry (2020) Vol. 89, Iss. 8, pp. 745-756
Open Access | Times Cited: 492
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Eric Karran, Bart De Strooper
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 4, pp. 306-318
Open Access | Times Cited: 485
Eric Karran, Bart De Strooper
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 4, pp. 306-318
Open Access | Times Cited: 485
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 475
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 475
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
Yun Zhang, Huaqiu Chen, Ran Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 358
Yun Zhang, Huaqiu Chen, Ran Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 358
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
Martin Tolar, Susan Abushakra, John A. Hey, et al.
Alzheimer s Research & Therapy (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 298
Martin Tolar, Susan Abushakra, John A. Hey, et al.
Alzheimer s Research & Therapy (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 298
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
Thomas K. Karikari, Andréa Lessa Benedet, Nicholas J. Ashton, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 2, pp. 429-442
Open Access | Times Cited: 272
Thomas K. Karikari, Andréa Lessa Benedet, Nicholas J. Ashton, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 2, pp. 429-442
Open Access | Times Cited: 272
Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease
Nils Korte, Ross Nortley, David Attwell
Acta Neuropathologica (2020) Vol. 140, Iss. 6, pp. 793-810
Open Access | Times Cited: 258
Nils Korte, Ross Nortley, David Attwell
Acta Neuropathologica (2020) Vol. 140, Iss. 6, pp. 793-810
Open Access | Times Cited: 258
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2381-2387
Open Access | Times Cited: 258
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2381-2387
Open Access | Times Cited: 258
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Rik Ossenkoppele, Ruben Smith, Niklas Mattsson, et al.
JAMA Neurology (2021) Vol. 78, Iss. 8, pp. 961-961
Open Access | Times Cited: 220
Rik Ossenkoppele, Ruben Smith, Niklas Mattsson, et al.
JAMA Neurology (2021) Vol. 78, Iss. 8, pp. 961-961
Open Access | Times Cited: 220
Biomarkers of aging
Hainan Bao, Jiani Cao, Mengting Chen, et al.
Science China Life Sciences (2023) Vol. 66, Iss. 5, pp. 893-1066
Open Access | Times Cited: 197
Hainan Bao, Jiani Cao, Mengting Chen, et al.
Science China Life Sciences (2023) Vol. 66, Iss. 5, pp. 893-1066
Open Access | Times Cited: 197
Nrf2: a dark horse in Alzheimer's disease treatment
Alsiddig Osama, Junmin Zhang, Juan Yao, et al.
Ageing Research Reviews (2020) Vol. 64, pp. 101206-101206
Closed Access | Times Cited: 183
Alsiddig Osama, Junmin Zhang, Juan Yao, et al.
Ageing Research Reviews (2020) Vol. 64, pp. 101206-101206
Closed Access | Times Cited: 183
Tauopathies: new perspectives and challenges
Yi Zhang, Kaimin Wu, Yang Liu, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 183
Yi Zhang, Kaimin Wu, Yang Liu, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 183
Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection
Shruti Shandilya, Sandeep Kumar, Niraj Kumar Jha, et al.
Journal of Advanced Research (2021) Vol. 38, pp. 223-244
Open Access | Times Cited: 182
Shruti Shandilya, Sandeep Kumar, Niraj Kumar Jha, et al.
Journal of Advanced Research (2021) Vol. 38, pp. 223-244
Open Access | Times Cited: 182
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Alexis Moscoso, Michel J. Grothe, Nicholas J. Ashton, et al.
Brain (2020) Vol. 144, Iss. 1, pp. 325-339
Open Access | Times Cited: 178
Alexis Moscoso, Michel J. Grothe, Nicholas J. Ashton, et al.
Brain (2020) Vol. 144, Iss. 1, pp. 325-339
Open Access | Times Cited: 178
Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
Sandra Villegas, AlejandroR Roda, Gabriel Serra-Mir, et al.
Neural Regeneration Research (2021) Vol. 17, Iss. 8, pp. 1666-1666
Open Access | Times Cited: 173
Sandra Villegas, AlejandroR Roda, Gabriel Serra-Mir, et al.
Neural Regeneration Research (2021) Vol. 17, Iss. 8, pp. 1666-1666
Open Access | Times Cited: 173
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
Konstantinos Avgerinos, Luigi Ferrucci, Dimitrios Kapogiannis
Ageing Research Reviews (2021) Vol. 68, pp. 101339-101339
Open Access | Times Cited: 172
Konstantinos Avgerinos, Luigi Ferrucci, Dimitrios Kapogiannis
Ageing Research Reviews (2021) Vol. 68, pp. 101339-101339
Open Access | Times Cited: 172
